Drug Safety Research Laboratories, Astellas Pharma Inc., 2-1-6, Kashima, Yodogawa-ku, Osaka 532-8514, Japan; Laboratory of Radiation Biology, Department of Biological Science, Graduate School of Science, Osaka Prefecture University, 1-2, Gakuen-cho, Naka-ku, Sakai, Osaka 599-8570, Japan.
Mutat Res. 2013 Sep;749(1-2):39-48. doi: 10.1016/j.mrfmmm.2013.06.001. Epub 2013 Jun 17.
Aneuploidy is a change in the number of chromosomes and an essential component in tumorigenesis. Therefore, accurate and sensitive detection of aneuploidy is important in screening for carcinogens. In vitro micronucleus (MN) assay has been adopted in the recently revised International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) S2 guideline and can be employed to predict both clastogenic and aneugenic chromosomal aberrations in interphase cells. However, distinguishing clastogens and aneugens is not possible using this assay. The Organization for Economic Co-operation and Development (OECD) guideline TG487 therefore recommends the use of centromere/kinetochore staining in micronuclei to differentiate clastogens from aneugens. Here, we analyzed numerical changes of a specific chromosome in cytokinesis-blocked binucleated cells by fluorescence in situ hybridization (FISH) using the specific centromere probe in human lymphoblastoid TK6 cells treated with aneugens (colcemid and vincristine) or clastogens (methyl methanesulfonate [MMS] and 4-nitroquinoline-1-oxide [4-NQO]). Colcemid and vincristine significantly increased the frequencies of nondisjunction and loss of FISH signals, while MMS and 4-NQO slightly increased only the frequency of loss of FISH signals. The loss of FISH signals of a specific chromosome from two to one per nucleus implies either a loss of a whole chromosome or an overlap of two signals. To distinguish a chromosome loss from signal overlap, we investigated the number of FISH signals and the fluorescent intensity of each signal per nucleus using a probe specific for whole chromosome 2 in binucleated TK6 cells and primary human lymphocytes treated with colcemid and MMS. By discriminating between chromosome loss and FISH signal overlap, we revealed that colcemid, but not MMS, induced a loss of a whole chromosome in primary lymphocytes and TK6 cells.
非整倍体是染色体数目的改变,是肿瘤发生的一个重要组成部分。因此,准确、灵敏地检测非整倍体对于致癌物质的筛选非常重要。体外微核(MN)试验已被最近修订的人用药物注册技术要求国际协调会议(ICH)S2 指导原则采用,并可用于预测有丝分裂间期细胞中的断裂剂和非整倍体染色体畸变。然而,该试验无法区分断裂剂和非整倍体诱导剂。因此,经济合作与发展组织(OECD)指南 TG487 建议使用微核中的着丝粒/动粒染色来区分断裂剂和非整倍体诱导剂。在这里,我们通过荧光原位杂交(FISH)分析了人淋巴母细胞 TK6 细胞中特定染色体的数值变化,这些细胞用非整倍体诱导剂(秋水仙素和长春新碱)或断裂剂(甲基甲磺酸酯[MMS]和 4-硝基喹啉 1-氧化物[4-NQO])处理后进行细胞分裂阻断形成双核细胞。秋水仙素和长春新碱显著增加了非整倍体和 FISH 信号丢失的频率,而 MMS 和 4-NQO 仅略微增加了 FISH 信号丢失的频率。从每个核的两个到一个特定染色体的 FISH 信号丢失意味着整条染色体的丢失或两个信号的重叠。为了区分染色体丢失和信号重叠,我们使用针对双核 TK6 细胞和用秋水仙素和 MMS 处理的原代人淋巴细胞的整条染色体 2 的特异性探针,研究了每个核的 FISH 信号数量和每个信号的荧光强度。通过区分染色体丢失和 FISH 信号重叠,我们揭示了秋水仙素而非 MMS 诱导了原代淋巴细胞和 TK6 细胞中整条染色体的丢失。